Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Toronto Stock Exchange  >  ProMIS Neurosciences, Inc.    PMN   CA74346M1095

PROMIS NEUROSCIENCES, INC.

(PMN)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Toronto Stock Exchange
02/18/2021 02/19/2021 02/22/2021 02/23/2021 02/24/2021 Date
0.145(c) 0.16(c) 0.145(c) 0.14(c) 0.135 Last
90 223 259 296 326 945 335 950 326 172 Volume
-6.45% +10.34% -9.38% -3.45% -3.57% Change
More quotes
Financials
Sales 2018 0,00 M 0,00 M 0,00 M
Net income 2018 -10,2 M -8,12 M -8,12 M
Net cash position 2018 2,43 M 1,94 M 1,94 M
P/E ratio 2018 -4,65x
Yield 2018 -
Sales 2019 0,00 M 0,00 M 0,00 M
Net income 2019 -7,40 M -5,91 M -5,91 M
Net cash position 2019 1,70 M 1,36 M 1,36 M
P/E ratio 2019 -4,59x
Yield 2019 -
Capitalization 40,6 M 32,3 M 32,4 M
EV / Sales 2018 135 184x
EV / Sales 2019 37 534x
Nbr of Employees -
Free-Float 90,1%
More Financials
Company
ProMIS Neurosciences Inc, formerly Amorfix Life Sciences Ltd, is a Canada-based development-stage biotech company. The Company discovers and develops precision therapeutics with companion diagnostics for early detection and treatment of neurodegenerative diseases, in particular Alzheimer's disease (AD) and amyotrophic lateral sclerosis (ALS). The assays are developed using its technologies, Epitope Protection and... 
More about the company
All news about PROMIS NEUROSCIENCES, INC.
02/03PROMIS NEUROSCIENCES : Offers Perspectives on Recent Progress in the Alzheimer's..
AQ
02/02PROMIS NEUROSCIENCES : Edging Up After Offering Perspectives on Recent Progress ..
MT
02/02PROMIS NEUROSCIENCES : Offers Perspectives on Recent Progress in the Alzheimer's..
PU
01/12PROMIS NEUROSCIENCES : Details Strategic Priorities for 2021
MT
01/12ProMIS Neurosciences Announces Strategic Priorities for 2021
GL
2020PROMIS NEUROSCIENCES : Year in review, looking forward to 2021
PU
2020PROMIS NEUROSCIENCES : Completes offering of special warrants
AQ
2020PROMIS NEUROSCIENCES : Completes Offering of Special Warrants
AQ
2020ProMIS Neurosciences Completes Offering of Special Warrants
GL
2020PROMIS NEUROSCIENCES : Completes offering of special warrants
PU
2020PROMIS NEUROSCIENCES : Announces Third Quarter 2020 Results
PU
2020PROMIS NEUROSCIENCES : Announces Third Quarter 2020 Results
AQ
2020PROMIS NEUROSCIENCES : Announces Third Quarter 2020 Results
AQ
2020ProMIS Neurosciences Announces Third Quarter 2020 Results
GL
2020PROMIS NEUROSCIENCES : Falls to Near 52-Week Low After FDA Committee Concludes A..
MT
More news
News in other languages on PROMIS NEUROSCIENCES, INC.

- No features available -

More news
Chart PROMIS NEUROSCIENCES, INC.
Duration : Period :
ProMIS Neurosciences, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PROMIS NEUROSCIENCES, INC.
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
 
Mean consensus -
Number of Analysts
Average target price
Last Close Price 0,14 
Spread / Highest target -
Spread / Average Target -
Spread / Lowest Target -
EPS Revisions
Managers and Directors
NameTitle
Elliot Goldstein President, Chief Executive Officer & Director
Daniel E. Geffken Chief Financial Officer
Eugene Williams Executive Chairman
Neil R. Cashman Director & Chief Scientific Officer
Johannes Minho Roth Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
PROMIS NEUROSCIENCES, INC.45.00%32
GILEAD SCIENCES, INC.10.49%79 825
WUXI APPTEC CO., LTD.10.10%58 463
VERTEX PHARMACEUTICALS-9.05%56 266
REGENERON PHARMACEUTICALS-2.64%48 743
BEIGENE, LTD.27.47%30 411